MET and glioblastoma: The involvement of the c-Met/TrkA-B pathway in the resistance of GBM to CDK4/6 inhibition presents a novel mechanism, suggesting that the simultaneous inhibition of c-Met/Trk should be taken into account in forthcoming clinical trials involving CDK4/6 [28].